公司资料
Theravance Biopharma 股价、新闻与催化剂
- 股票代码:
- TBPH
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
16.92 USD (-0.29%)
收盘价
最后更新: 2026年8月17日
803M USD
市值
股价为何变动
As of Aug 17, 2026, TBPH closed down 0.29% at $16.92. No new same-company headline was identified in the current news window.
公司概览
Respiratory Medicines
Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.
YUPELRI
YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Theravance receives collaboration revenue tied to U.S. sales. Following the outcome of the CYPRESS study, the company is winding down that clinical program and restructuring around its commercial asset and remaining strategic opportunities.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。